We show that second-generation EGFR806-CAR T cells with a short spacer can eradicate malignant glioma in a xenograft mouse model via intracranial delivery, and that CAR T cell activation is specific to tumor-expressed EGFR. Here, EGFR is linked to malignant glioma.